

2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| SV Growth Opportunity Fund III | March 2026 | Indefinite | $22M | 27 |
| SemperVirens Capital Fund IV | March 2026 | Indefinite | $38M | 45 |
| SemperVirens Capital Fund III NQP | December 2022 | Indefinite | $1.9M | 23 |
| SV Growth Opportunity Fund II | July 2022 | Indefinite | $18M | 31 |
| SemperVirens Capital Fund III | July 2022 | Indefinite | $99M | 80 |
| SV Growth Opportunity Fund II NQP | July 2022 | Indefinite | $658,333 | 10 |
| SV Opportunity Fund I | July 2021 | Indefinite | $18M | 63 |
| SemperVirens Capital Fund II | July 2020 | $50M | $45M | 103 |
| SEMPERVIRENS CAPITAL FUND | October 2018 | $15M | $14M | 67 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
7 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Allison GatesNot on the current fund | Quiet | Digital health | 1 | 0 |
| Colin TobiasNot on the current fund | Quiet | None listed | 0 | 0 |
| Greg Golub | Quiet | None listed | 0 | 0 |
| Robby PetersNot on the current fund | Quiet | None listed | 0 | 0 |
| Robert Peters | Quiet | None listed | 0 | 0 |
| S. HonigNot on the current fund | Quiet | Fintech | 1 | 0 |
| Steven KimNot on the current fund | Quiet | Medical devices, Digital health, E-commerce & marketplaces | 7 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Categories of SemperVirens’s own portfolio companies, based on 8 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of SemperVirens’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Verdis Seed | 6 | Adgorithmics, BAK Festivals, Claria Medical, Dream Management, MIRAMAR LABS, Voluware |
| Alliance Of Angels Seed | 1 | Kin Insurance |
| August Capital | 1 | Kin Insurance |
| Commerce Ventures | 1 | Kin Insurance |
| Lobby Capital | 1 | Kin Insurance |
| QED | 1 | Kin Insurance |
| Third Prime | 1 | Adgorithmics |
| Westlake Biopartners | 1 | Kin Insurance |
A shared board seat: a company where filings name a SemperVirens partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.